Cardiovascular implication risks of Vioxx comparable to other NSAIDs.

Published: 2001-11-08 06:57:00

Updated: 2001-11-08 06:57:00

MSD's Vioxx, a COX-2 selective inhibitor NSAID, showed a comparable risk level in the cardiovascular side effects with other placebo and 4 NSAIDs according to the latest journal report of "Circulation".

The journal described a similar occurrence frequency of the above cardiovascular implicatio...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK